Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 4/2016

Open Access 01-04-2016

Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC

Authors: Carole Siani, Christian de Peretti, Aurélie Millier, Laurent Boyer, Mondher Toumi

Published in: Quality of Life Research | Issue 4/2016

Login to get access

Abstract

Objective

The clinical symptoms of schizophrenia are associated with serious social, quality of life and functioning alterations. Typically, data on health utilities are not available in clinical studies in schizophrenia. This makes the economic evaluation of schizophrenia treatments challenging. The purpose of this article was to provide a mapping function to predict unobserved utility values in patients with schizophrenia from the available clinical and socio-demographic information.

Methods

The analysis was performed using data from EuroSC, a 2-year, multi-centre, cohort study conducted in France (N = 288), Germany (N = 618), and the UK (N = 302), totalling 1208 patients. Utility was calculated based on the EQ-5D questionnaire. The relationships between the utility values and the patients’ socio-demographic and clinical characteristics (Positive and Negative Syndrome Scale—PANSS, Calgary Depression Scale for Schizophrenia—CDSS, Global Assessment of Functioning—GAF, extra-pyramidal symptoms measured by Barnes Akathisia Scale—BAS, age, sex, country, antipsychotic type) were modelled using a random and a fixed individual effects panel linear model.

Results

The analysis demonstrated the prediction ability of the used parameters for estimating utility measures in patients with schizophrenia. Although there are small variations between countries, the same variables appear to be the key predictors. From a clinical perspective, age, gender, psychopathology, and depression were the most important predictors associated with the EQ-5D.

Conclusion

This paper proposed a reliable, robust and easy-to-apply mapping method to estimate EQ-5D utilities based on demographic and clinical measures in schizophrenia.
Appendix
Available only for authorised users
Literature
1.
Addington, D., Addington, J., & Schissel, B. (1990). A depression rating scale for schizophrenics. Schizophrenia Research, 3(4), 247–251.CrossRefPubMed
2.
Aki, H., Tomotake, M., Kaneda, Y., et al. (2008). Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia. Psychiatry Research, 158(1), 19–25.CrossRefPubMed
3.
Aksaray, G., Oflu, S., Kaptanoglu, C., & Bal, C. (2002). Neurocognitive deficits and quality of life in outpatients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26(6), 1217–1219.CrossRefPubMed
4.
Ara, R., Kearns, B., vanHout, B. A., & Brazier, J. E. (2014). Predicting preference-based utility values using partial proportional odds models. BMC Res Notes, 7, 438.CrossRefPubMedPubMedCentral
5.
Assemblee Nationale et Senat. Data les and individual liberties (amended by the act of 6 August 2004 relating to the protection of individuals with regard to the processing of personal data). Journal ociel de la Republique Francaise 2004; Act No. 78-17 of 6 January 1978 on Data Processing.
6.
Barnes, T. R. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.CrossRefPubMed
7.
Bebbington, P. E., Angermeyer, M., Azorin, J. M., et al. (2005). The European Schizophrenia Cohort (EuroSC): A naturalistic prognostic and economic study. Social Psychiatry and Psychiatric Epidemiology, 40(9), 707–717.CrossRefPubMed
8.
Bechdolf, A., Klosterkotter, J., Hambrecht, M., et al. (2003). Determinants of subjective quality of life in post acute patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 253(5), 228–235.CrossRefPubMed
9.
Bell, M., Milstein, R., Beam-Goulet, J., et al. (1992). The positive and negative syndrome scale and the brief psychiatric rating scale. Reliability, comparability, and predictive validity. Journal of Nervous & Mental Disease, 180(11), 723–728.CrossRef
10.
Beresniak, A., Russell, A. S., Haraoui, B., et al. (2007). Advantages and limitations of utility assessment methods in rheumatoid arthritis. Journal of Rheumatology, 34(11), 2193–2200.PubMed
11.
12.
Braga, R. J., & Mendlowicz, M. V. (2005). Marrocos RrP, Figueira IL. Anxiety disorders in outpatients with schizophrenia: Prevalence and impact on the subjective quality of life. Journal of Psychiatric Research, 39(4), 409–414.CrossRefPubMed
13.
Brazier, J., Jones, N., & Kind, P. (1993). Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Quality of Life Research, 2(3), 169–180.CrossRefPubMed
14.
Dickerson, F. B., Ringel, N. B., & Parente, F. (1998). Subjective quality of life in out-patients with schizophrenia: Clinical and utilization correlates. Acta Psychiatrica Scandinavica, 98(2), 124–127.CrossRefPubMed
15.
Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRefPubMed
16.
Eack, S. M., & Newhill, C. E. (2007). Psychiatric symptoms and quality of life in schizophrenia: A meta-analysis. Schizophrenia Bulletin, 33(5), 1225–1237.CrossRefPubMedPubMedCentral
17.
Endicott, J., Spitzer, R. L., Fleiss, J. L., & Cohen, J. (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33(6), 766–771.CrossRefPubMed
18.
Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997). Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23(4), 637–651.CrossRefPubMed
19.
Greene, W. H. (2002). Econometric analysis (4th ed.). Upper Saddle River, New Jersey: Prentice Hall.
20.
Heslegrave, R. J., Awad, A. G., & Voruganti, L. N. (1997). The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. Journal of Psychiatry and Neuroscience, 22(4), 235–243.PubMedPubMedCentral
21.
Hofer, A., Baumgartner, S., Edlinger, M., et al. (2005). Patient outcomes in schizophrenia I: Correlates with sociodemographic variables, psychopathology, and side effects. European Psychiatry: The Journal of the Association of European Psychiatrists, 20(5–6), 386–394.CrossRef
22.
Hofer, A., Rettenbacher, M. A., Widschwendter, C. G., et al. (2006). Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. European Archives of Psychiatry and Clinical Neuroscience, 256(4), 246–255.CrossRefPubMed
23.
Hurst, N. P., Jobanputra, P., Hunter, M., et al. (1994). Validity of Euroqol–a generic health status instrument–in patients with rheumatoid arthritis. Economic and health outcomes research group. British Journal of Rheumatology, 33(7), 655–662.CrossRefPubMed
24.
Kay, S. R., Opler, L. A., & Lindenmayer J. P. (1989) The positive and negative syndrome scale (PANSS): Rationale and standardisation. British Journal of Psychiatry—Supplementum (7), 59–67.
25.
Kemmler, G., Holzner, B., Neudorfer, C., et al. (1997). General life satisfaction and domain-specific quality of life in chronic schizophrenic patients. Quality of Life Research, 6(3), 265–273.CrossRefPubMed
26.
Lenert, L. A., Rupnow, M. F., & Elnitsky, C. (2005). Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health & Quality of Life Outcomes, 3, 57.CrossRef
27.
Lenert, L. A., Sturley, A. P., Rapaport, M. H., et al. (2004). Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores.[Erratum appears in Schizophr Res. 2005 Dec 1;80(1):135–6]. Schizophrenia Research, 71(1), 155–165.CrossRefPubMed
28.
Leucht, S., Burkard, T., Henderson, J., et al. (2007). Physical illness and schizophrenia: A review of the literature. Acta Psychiatrica Scandinavica, 116(5), 317–333.CrossRefPubMed
29.
Mavranezouli, I. (2010). A Review and critique of studies reporting utility values for schizophrenia-related health states. Pharmacoeconomics, 28(12), 1109–1121.CrossRefPubMed
30.
McCrone, P., Patel, A., Knapp, M., et al. (2009). A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. The Journal of Mental Health Policy & Economics, 12(1), 27–31.
31.
McFadden, D. (1973). Econometric models of probabilistic choice. In Z. Griliches & M. Intriligator (Eds.), Handbook of econometrics. Cambridge: MIT Press.
32.
NICE (2008). Guide to the methods of technology appraisal. Technical report, National Institute of Health and Clinical Excellence (NICE), London.
33.
Norman, R. M., Malla, A. K., McLean, T., et al. (2000). The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the quality of life scale. Acta Psychiatrica Scandinavica, 102(4), 303–309.CrossRefPubMed
34.
Pinikahana, J., Happell, B., Hope, J., & Keks, N. A. (2002). Quality of life in schizophrenia: A review of the literature from 1995 to 2000. International Journal of Mental Health Nursing, 11(2), 103–111.CrossRefPubMed
35.
Reine, G., Simeoni, M. C., Auquier, P., et al. (2005). Assessing health-related quality of life in patients suffering from schizophrenia: A comparison of instruments. European Psychiatry: the Journal of the Association of European Psychiatrists, 20(7), 510–519.CrossRef
36.
Rocca, P., Bellino, S., Calvarese, P., et al. (2005). Depressive and negative symptoms in schizophrenia: Different effects on clinical features. Comprehensive Psychiatry, 46(4), 304–310.CrossRefPubMed
37.
Siani, C., de Peretti, C., Castelli, C., et al. (2011). Uncertainty around the incremental cost utility ratio accounting for mapping prediction: Application to hepatitis C.
38.
Smith, T. E., Hull, J. W., Goodman, M., et al. (1999). The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. Journal of Nervous & Mental Disease, 187(2), 102–108.CrossRef
39.
Strejilevich, S. A., Palatnik, A., Avila, R., et al. (2005). Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. Psychiatry Research, 133(2–3), 277–280.CrossRefPubMed
40.
van Agt, H. M., Essink-Bot, M. L., Krabbe, P. F., & Bonsel, G. J. (1994). Test-retest reliability of health state valuations collected with the EuroQol questionnaire. Social Science and Medicine, 39(11), 1537–1544.CrossRefPubMed
41.
Ware, J. E, Jr, & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed
42.
World Medical Association. (2008). Declaration of Helsinki. Ethical principles for medical research involving human subjects. Seoul: General Assembly.
43.
Yamauchi, K., Aki, H., Tomotake, M., et al. (2008). Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry and Clinical Neurosciences, 62(4), 404–411.CrossRefPubMed
Metadata
Title
Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC
Authors
Carole Siani
Christian de Peretti
Aurélie Millier
Laurent Boyer
Mondher Toumi
Publication date
01-04-2016
Publisher
Springer International Publishing
Published in
Quality of Life Research / Issue 4/2016
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-1120-6

Other articles of this Issue 4/2016

Quality of Life Research 4/2016 Go to the issue

OriginalPaper

Employment and insurance outcomes and factors associated with employment among long-term thyroid cancer survivors: a population-based study from the PROFILES registry

OriginalPaper

Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis

OriginalPaper

The roles of contextual and individual social determinants of oral health-related quality of life in Brazilian adults

OriginalPaper

Linkage between the PROMIS® pediatric and adult emotional distress measures

OriginalPaper

Paving the way for the use of the SDQ in economic evaluations of school-based population health interventions: an empirical analysis of the external validity of SDQ mapping algorithms to the CHU9D in an educational setting

OriginalPaper

Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms